Skip to main content

Table 2 Baseline demographic and clinical characteristics of HF, non-HF patients from study group

From: Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure

Characteristics

HF patients (n = 9)

Non-HF patients (n = 8)

P value

Men

6 (66.7%)

7 (87.5%)

0.576

Women

3 (33.3%)

1 (12.5%)

0.576

Age (years)

60.1 ± 14.3

51.8 ± 7.2

0.147

BMI (kg/m2)

26.8 ± 3.1

25.6 ± 1.6

0.323

Hypertension

3 (33.3%)

1 (12.5%)

0.576

Diabetes

2 (22.2%)

1 (12.5%)

>0.999

Previous MI

0 (0%)

0 (0%)

NA

Smoking

3 (33.3%)

5 (62.5%)

0.347

Hypercholesterolemia

5 (55.6%)

4 (50%)

>0.999

AMI

8 (88.9%)

3 (42.9%)

0.106

NT-proBNP (pg/mL)a

918.3 ± 848.5

62 ± 14.1

<0.001

LVEF (%)a

39.3 ± 8.4

66.8 ± 1.9

0.001

Medications

Aspirin

9 (100%)

8 (100%)

NA

Clopidogrel

8 (88.9%)

8 (100%)

>0.999

Beta blockers

9 (100%)

8 (100%)

NA

ACE inhibitors

9 (100%)

8 (100%)

NA

Statins

9 (100%)

8 (100%)

NA

Diuretics

7 (77.8%)

1 (12.5%)

0.015

  1. aNT-proBNP, LVEF measured 6 months after AMI.
  2. Data are presented as mean value ± standard deviation or number or percentage of patients. P value <0.05 was considered significant.
  3. ACE, angiotensin-converting enzyme; AMI, anterior myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide.